Final results from a landmark study looking at the use of GSK's Mosquirix malaria vaccine alongside antimalarial drugs and other measures have shown a 90%-plus reduction in cases. The study in ...

The expected vaccines, known as RTS,S/AS01 (Mosquirix), have been proven to reduce malaria cases and mortality among young children in large clinical trials across Africa. Malaria remains serious ...

The RTS,S vaccine (Mosquirix) was developed by GlaxoSmithKline (GSK), a British multinational pharmaceutical company, in partnership with the PATH Malaria Vaccine Initiative, a non-profit ...

The continent is being drenched in an avalanche of medical disinformation with the aim of undermining western influence ...

Nigeria has received 846,000 doses of the RTS, S/AS01 (Mosquirix) vaccine from Gavi, the Vaccine Alliance, to combat malaria. This vaccine, proven to reduce malaria cases and mortality among young ...

Nigeria has received 846,000 doses of the RTS, S/AS01 (Mosquirix) vaccine from Gavi, the Vaccine Alliance, to combat malaria. This vaccine, proven to reduce malaria cases and mortality among young ...

The expected vaccines, known as RTS, S/AS01 (Mosquirix), have been proven to reduce malaria cases and mortality among young children in large clinical trials across Africa. Nigeria will be the ...

The News Agency of Nigeria (NAN) reports that large clinical trials in Africa proved the vaccine, RTS,S/AS01 (Mosquirix) as effective in reducing contracting malaria cases and mortality among ...

Malaria remains one of the most persistent public health challenges in Africa, despite decades of concerted efforts to reduce ...

Maternal antibodies passed across the placenta can interfere with the response to the malaria vaccine, which would explain its lower efficacy in infants under five months of age, according to new ...

Nigeria has received 846,000 doses of a groundbreaking malaria vaccine from development partners to reduce the country’s high incidence of the disease, especially among children and other ...